{"protocolSection":{"identificationModule":{"nctId":"NCT06069544","orgStudyIdInfo":{"id":"BNT165-02"},"organization":{"fullName":"BioNTech SE","class":"INDUSTRY"},"briefTitle":"A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria","officialTitle":"A Randomized, Dose-escalation Phase I/IIa Trial With Controlled Human Malaria Infection to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of an Investigational RNA-based Vaccine for Prevention of P. Falciparum Malaria in Healthy Malaria naïve Adults"},"statusModule":{"statusVerifiedDate":"2026-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-11-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-05-28","type":"ACTUAL"},"completionDateStruct":{"date":"2026-03-20","type":"ACTUAL"},"studyFirstSubmitDate":"2023-09-29","studyFirstSubmitQcDate":"2023-09-29","studyFirstPostDateStruct":{"date":"2023-10-06","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-06-29","resultsFirstSubmitQcDate":"2026-08-06","resultsFirstPostDateStruct":{"date":"2026-08-28","type":"ACTUAL"},"dispFirstSubmitDate":"2026-04-08","dispFirstPostDateStruct":{"date":"2026-08-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-08-06","lastUpdatePostDateStruct":{"date":"2026-08-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BioNTech SE","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This was a randomized, dose-escalation Phase I/IIa study to evaluate safety, tolerability, immunogenicity and efficacy of an investigational RNA-based vaccine (BNT165e) for prevention of P. falciparum malaria in healthy malaria-naive adults.\n\nThe multi-antigen malaria vaccine (designated BNT165e) is a combination of three distinct RNAs, BNT165c and BNT165d (composed of BNT165d1 and BNT165d2), encoding P. falciparum antigens encapsulated in lipid nanoparticles. The BNT165c RNA encodes the full Plasmodium falciparum circumsporozoite protein. The BNT165d1 and BNT165d2 RNAs both encode conserved, immunogenic segments of liver stage-expressed proteins.","detailedDescription":"Part A of this study was observer-blind and assessed the reactogenicity, safety, and immunogenicity of up to 9 dose combinations in a 3-dose regimen of the 3 components of BNT165e. Participants were randomized 5:1 active:placebo.\n\nIn Cohorts 1 to 9, the initial two doses of the investigational medicinal product (IMP) were administered \\~8 weeks apart and the third dose was administered \\~18 weeks after the second dose (given at 0-2-6 months). In Cohort 10, each of the three doses of IMP was administered 28 days apart (given at 0-1-2 months).\n\nParticipants who were out of window for dosing in the event of a study pause could have been discontinued from further vaccination. If a participant was discontinued either from further vaccination or from the study, the sponsor could decided to replace this participant with a new participant. Participants were randomized to the IMP in the open cohort until that cohort has filled. Per protocol, the number of participants was increased to 163 due to participant replacement or re-enrollment.\n\nThe study duration was up to a maximum of 89 weeks for each participant in Cohorts 1 to 9 (planned study duration of 84 weeks plus 30 days window extension for Dose 3 due to study pause), and 66 weeks for each participant in Cohort 10.\n\nThe initially planned Part B with a controlled human malaria infection model was not performed."},"conditionsModule":{"conditions":["Malaria"],"keywords":["RNA vaccine","Vaccine","Active immunization against malaria","Plasmodium falciparum"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Observer-blinded","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":163,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BNT165c 10 micrograms (mcg)","type":"EXPERIMENTAL","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c"]},{"label":"BNT165c 30 mcg","type":"EXPERIMENTAL","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c"]},{"label":"BNT165c 70 mcg","type":"EXPERIMENTAL","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c"]},{"label":"BNT165c 100 mcg","type":"EXPERIMENTAL","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c"]},{"label":"BNT165d 30 mcg","type":"EXPERIMENTAL","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165d"]},{"label":"BNT165c 30 mcg + BNT165d 10 mcg","type":"EXPERIMENTAL","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c","Biological: BNT165d"]},{"label":"BNT165c 10 mcg + BNT165d 30 mcg","type":"EXPERIMENTAL","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c","Biological: BNT165d"]},{"label":"BNT165c 30 mcg + BNT165d 30 mcg","type":"EXPERIMENTAL","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c","Biological: BNT165d"]},{"label":"BNT165c 70 mcg + BNT165d 30 mcg","type":"EXPERIMENTAL","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","interventionNames":["Biological: BNT165c","Biological: BNT165d"]},{"label":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","type":"EXPERIMENTAL","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months.","interventionNames":["Biological: BNT165c","Biological: BNT165d"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nIncludes placebo participants of all dose levels with a 0-2-6 months dose regimen.","interventionNames":["Other: Placebo"]},{"label":"Placebo (0-1-2)","type":"PLACEBO_COMPARATOR","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nDoses were given at 0-1-2 months.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"BNT165c","description":"Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection","armGroupLabels":["BNT165c 10 mcg + BNT165d 30 mcg","BNT165c 10 micrograms (mcg)","BNT165c 100 mcg","BNT165c 30 mcg","BNT165c 30 mcg + BNT165d 10 mcg","BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","BNT165c 30 mcg + BNT165d 30 mcg","BNT165c 70 mcg","BNT165c 70 mcg + BNT165d 30 mcg"]},{"type":"BIOLOGICAL","name":"BNT165d","description":"Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection","armGroupLabels":["BNT165c 10 mcg + BNT165d 30 mcg","BNT165c 30 mcg + BNT165d 10 mcg","BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","BNT165c 30 mcg + BNT165d 30 mcg","BNT165c 70 mcg + BNT165d 30 mcg","BNT165d 30 mcg"]},{"type":"OTHER","name":"Placebo","description":"Isotonic NaCl solution (0.9%)","armGroupLabels":["Placebo","Placebo (0-1-2)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number and Percentage of Participants With Solicited Local Reactions at the Injection Site","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) and pre-listed (that is, solicited) in the e-diary. Solicited local reactions included: pain at the injection site, erythema/redness, and induration/swelling. The intensity of AEs was graded by the study participant. Confirmation by an investigator or medically qualified person was required for all Grade 3 or 4 reactogenicity events. Grades were defined as: Grade 1 - Mild; does not interfere with the study participant's activity; Grade 2 - Moderate; interferes with the study participant's activity; Grade 3 - Severe; prevents study participant's daily activity; and Grade 4 - Potentially life-threatening; emergency room visit or hospitalization for severe pain.\n\nParticipants may have been counted more than once if they reported multiple episodes of the event for the specified doses.","timeFrame":"Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)"},{"measure":"Number and Percentage of Participants With Solicited Systemic Reactions","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) and pre-listed (that is, solicited) in the e-diary. Solicited systemic reactions included: vomiting, diarrhea, headache, fatigue/tiredness, muscle pain/joint pain, and fever. The intensity of AEs was graded by the participant but only an investigator or medically qualified person was able to classify a systemic reaction as Grade 3 or 4. Grades were defined as: Grade 1 - Mild; does not interfere with the study participant's activity; Grade 2 - Moderate; some interference with the study participant's activity; Grade 3 - Severe; prevents the trial participant's daily routine activity; and Grade 4 - Potentially life-threatening; Emergency room visit or hospitalization. Fever was categorized as 38.0 - 38.4 °C, 38.5 - 38.9 °C, 39.0 - 40.0 °C \\& \\>40.0 °C. Participants may have been counted more than once if they reported multiple episodes of the event for the specified doses.","timeFrame":"Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)"},{"measure":"Number of Participants With at Least One Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered with a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment. The intensity of AEs was graded by the investigator. Grade 1 - Mild; does not interfere with the trial subject's usual function; Grade 2 - Moderate; interferes to some extend with the trial subject's usual function Grade 3 - Severe; interferes significantly with the trial subject's usual function; and Grade 4 - Potentially life-threatening; life-threatening consequences, urgent intervention required. Participants may have been counted more than once if they reported multiple episodes of the event for the different doses.\n\nIncludes all unsolicited AEs and also solicited events that persisted beyond 7 days post-dose, qualify as an SAE, or are delayed local reactions.","timeFrame":"From administration of each IMP dose (i.e., Dose 1, Dose 2, and Dose 3) up to 28 days after the respective IMP dose"},{"measure":"Number of Participants With at Least One Medically Attended Adverse Event (MAAE)","description":"An MAAE was defined as an AE for which the participants received medical attention defined as hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.\n\nIncludes all unsolicited AEs and also solicited events that qualify as an MAAE.","timeFrame":"From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months."},{"measure":"Number of Participants With at Least One Serious Adverse Event (SAE)","description":"An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death or was life-threatening. It also included any event requiring hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, caused a congenital anomaly or birth defect, or any other event determined as SAE as per medical or scientific judgment.\n\nIncludes all unsolicited AEs and solicited events that qualify as an SAE.","timeFrame":"From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months."}],"secondaryOutcomes":[{"measure":"Descriptive Statistics on Antibody Levels (Including Geometric Means and 95% Confidence Interval) at Assessed Timepoints","description":"For each cohort - Anti-CSP immunoglobulin G","timeFrame":"Up to 365 days after last received IMP dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have given informed consent by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.\n* Were willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions and other requirements of the study. This included that they were able to understand and follow study-related instructions.\n* Were aged 18 to 55 years, have a body mass index over 18.5 kg/m\\^2 and under 35 kg/m\\^2 and weighed at least 45 kg at Visit 0.\n* Were healthy, in the clinical judgment of the investigator based on volunteer-reported medical history data, and physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory test outcomes at Visit 0.\n\n  * Note: Healthy volunteers with pre-existing stable disease (e.g., obesity, hypertension), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 90 days before Visit 0, could have been included.\n* Agreed not to enroll in another study with an IMP starting from Visit 0 and until 12 weeks after receiving Dose 3.\n* Have not traveled and agreed not to travel to a malaria-endemic region, as defined per Centers for Disease Control and Prevention (CDC) (https://www.cdc.gov/malaria/travelers/country\\_table/a.html) starting 6 months before Visit 0 and continuously until 28 days after receiving Dose 3.\n* Negative human immunodeficiency virus -1 and -2 blood test result at Visit 0.\n* Negative Hepatitis B surface antigen test result at Visit 0 and negative anti-Hepatitis C virus (anti-HCV) antibodies, or negative HCV polymerase chain reaction test result if the anti-HCV is positive at Visit 0.\n* Volunteers of childbearing potential (VOCBP) that had a negative serum beta-human chorionic gonadotropin pregnancy test result at Visit 0 and negative urine pregnancy test results before each IMP administration. Volunteers born female who were postmenopausal or permanently sterilized were not be considered VOCBP.\n* VOCBP who agreed to practice a highly effective form of contraception starting at Visit 0 and continuously until 90 days after receiving Dose 3.\n* VOCBP who agreed not to donate or cryopreserve eggs (ova, oocytes) for the purposes of assisted reproduction during study, starting at Visit 0 and continuously until 90 days after receiving Dose 3.\n* Men who have not had a vasectomy and are sexually active with partners of childbearing potential and who agreed to use condoms and to practice a highly effective form of contraception with their sexual partners of childbearing potential during the study, starting at Visit 0 and continuously until 90 days after receiving Dose 3.\n* Men who were willing to refrain from sperm donation, starting at Visit 0 and continuously until 90 days after receiving Dose 3.\n\nExclusion Criteria:\n\n* History of Plasmodium parasitemia (any species) based on volunteer-reported medical history.\n* Prior residence for ≥6 months continuously in a malaria-endemic region as defined per CDC (https://www.cdc.gov/malaria/travelers/country\\_table/a.html) at any point during their lifetime.\n* Breastfeeding or intending to become pregnant or to father children starting with Visit 0 and continuously until 90 days after receiving Dose 3.\n* History of any serious adverse reactions to vaccines or to vaccine components such as lipids, and including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from participation: a volunteer who had an anaphylactic adverse reaction to pertussis vaccine as a child).\n* Presence or history of the following medical conditions:\n\n  1. Uncontrolled or moderate or severe respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease); symptoms of asthma severity as defined in the US National Asthma Education and Prevention Program Expert Panel report, 2020 - e.g., exclude a volunteer who:\n\n     * Used a short-acting rescue inhaler (typically a beta 2 agonist) daily, or\n     * Used high dose inhaled corticosteroids (per American Academy of Allergy Asthma and Immunology), or\n     * In the year prior to study inclusion has had either of the following:\n\n       * Greater than one exacerbation of symptoms treated with oral/parenteral corticosteroids\n       * Needed hospitalization, or intubation for asthma.\n  2. History of Diabetes mellitus type 1 or type 2, including cases controlled with diet alone or elevated hemoglobin A1C ≥6.5% at screening (not excluded: history of isolated gestational diabetes).\n  3. Hypertension:\n\n     * If a person had a history of hypertension, or elevated blood pressure detected during screening, the person was excluded for blood pressure that was not well controlled. Well controlled blood pressure was defined as consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤150 mm Hg systolic and ≤100 mm Hg diastolic at screening and enrollment.\n  4. Malignancy within 5 years of screening, excluding localized basal or squamous cell skin cancer.\n  5. Any presence or history of cardiovascular diseases, (e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias), unless such disease was not considered relevant for participation in this study in the investigator's judgment.\n  6. An abnormal screening ECG (i.e., showing the corrected QT interval by Fridericia \\[QTcF\\] greater than 450 ms; significant ST-T wave changes suggestive of myocardial ischemia or of an acute or indeterminate-age myocardial infarction; left ventricular hypertrophy; any non-sinus rhythm including isolated premature ventricular contractions; complete right or left bundle branch block \\[QRS greater than 120 ms\\]; second-or third-degree atrioventricular block); or other clinically significant abnormalities on the ECG at the investigator's discretion.\n  7. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions).\n  8. Seizure disorder: History of seizure(s) within the past 3 years or had used medications in order to prevent or treat seizure(s) at any time within the past 3 years.\n* Documented major psychiatric illness, including bipolar disorder, major depressive disorder, schizophrenia, autism, and attention deficit-hyperactivity disorder that at the discretion of the investigator could have interfered with participation and follow-up as outlined by the study.\n* The following diseases associated with immune dysregulation:\n\n  * Primary immunodeficiencies.\n  * History of solid organ or bone marrow transplantation.\n  * Asplenia: any condition resulting in the absence of a functional spleen.\n  * Existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc.\n* Previous vaccination with an approved or investigational malaria vaccine at any time or having taken part in a human malaria challenge study.\n* Receipt of any investigational product within 28 days before Visit 0.\n* Any planned non-study vaccinations starting at Visit 0 and continuously until 28 days after Dose 3.\n\n  * Note: Seasonal influenza and Coronavirus Disease 2019 (COVID-19) vaccines were allowed; however, they should been administered at least 14 days before or 28 days after any IMP administration. Emergency vaccinations, such as tetanus, were allowed to be administered when medically indicated.\n* Received blood/plasma products, monoclonal antibodies or immunoglobulin within 120 days before Visit 1 or planned administration starting at Visit 0 and continuously until the last study visit (365 days after Dose 3).\n* Received allergy treatment with antigen injections within 28 days before and after each IMP administration.\n* Ongoing or planned treatment with immunosuppressive therapy, including systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent) starting at Visit 0 and continuously until 28 days after Dose 3. Intraarticular, intrabursal, or topical (skin or eyes) corticosteroids were permitted.\n* Had a history of alcohol abuse or drug addiction within 1 year before Visit 0 or had a history (within the past 5 years) of substance abuse, which in the opinion of the investigator, could have compromised their wellbeing if they participated as participants in the study, or that could have prevented, limited, or confounded the protocol specified assessments.\n* Any existing condition which may have affected vaccine injection and/or assessment of local reactions at the injection site, e.g., tattoos, severe scars, etc.\n* Were vulnerable individuals as per International Council for Harmonisation (ICH) E6 definition, i.e., were individuals whose willingness to volunteer in a clinical study may been unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.\n* Any screening hematology and/or blood chemistry laboratory value (per the US FDA 2007) that met the definition of a Grade ≥2 abnormality or a Grade 1 abnormality at the investigator's discretion at Visit 0 or a Visit 0 troponin above the reference range. Individuals with abnormal but not clinically significant parameters not included in the toxicity guidance may have been considered eligible at discretion of investigator, with the exception of abnormal troponin values.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"BioNTech Responsible Person","affiliation":"BioNTech SE","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"AMR Tempe","city":"Tempe","state":"Arizona","zip":"85281","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"University of Maryland, Center for Vaccine Development","city":"Baltimore","state":"Maryland","zip":"21201","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"AMR Las Vegas","city":"Las Vegas","state":"Nevada","zip":"89119","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"AMR Knoxville","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Clinical Trials of Texas","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]},"referencesModule":{"references":[{"pmid":"40245769","type":"DERIVED","citation":"Mo AX, McGugan G, Pesce JT. Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development. Vaccine. 2025 Apr 30;54:127009. doi: 10.1016/j.vaccine.2025.127009. Epub 2025 Apr 16."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"BNT165c 10 mcg","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"FG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months."},{"id":"FG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%). Includes placebo participants of all dose levels with a 0-2-6 months dose regimen."},{"id":"FG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%). Doses were given at 0-1-2 months."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"26"},{"groupId":"FG008","numSubjects":"30"},{"groupId":"FG009","numSubjects":"10"},{"groupId":"FG010","numSubjects":"25"},{"groupId":"FG011","numSubjects":"2"}]},{"type":"Vaccinated with Dose 1","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"26"},{"groupId":"FG008","numSubjects":"30"},{"groupId":"FG009","numSubjects":"10"},{"groupId":"FG010","numSubjects":"25"},{"groupId":"FG011","numSubjects":"2"}]},{"type":"Vaccinated with Dose 2","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"9"},{"groupId":"FG007","numSubjects":"15"},{"groupId":"FG008","numSubjects":"15"},{"groupId":"FG009","numSubjects":"10"},{"groupId":"FG010","numSubjects":"19"},{"groupId":"FG011","numSubjects":"2"}]},{"type":"Vaccinated with Dose 3","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"9"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"8"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"2"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"9"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"7"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"1"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"24"},{"groupId":"FG008","numSubjects":"30"},{"groupId":"FG009","numSubjects":"3"},{"groupId":"FG010","numSubjects":"13"},{"groupId":"FG011","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"1"}]},{"type":"Subject incarcerated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Follow-up after treatment discontinuation as per protocol","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"15"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"4"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Participant does not wish to continue receiving IMP but still consents to safety follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Participant moved out of the country","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"}]},{"type":"Study participation ongoing","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"5"},{"groupId":"FG011","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis was performed on the safety set that included all participants who received at least one dose of the investigational medicinal product (IMP).","groups":[{"id":"BG000","title":"BNT165c 10 Micrograms (mcg)","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"BG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months."},{"id":"BG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%). Includes placebo participants of all dose levels with a 0-2-6 months dose regimen."},{"id":"BG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%). Doses were given at 0-1-2 months."},{"id":"BG012","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"26"},{"groupId":"BG008","value":"30"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"25"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"163"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.7","spread":"10.71"},{"groupId":"BG001","value":"38.3","spread":"8.68"},{"groupId":"BG002","value":"40.8","spread":"10.2"},{"groupId":"BG003","value":"37.0","spread":"9.52"},{"groupId":"BG004","value":"38.7","spread":"9.57"},{"groupId":"BG005","value":"36.7","spread":"7.44"},{"groupId":"BG006","value":"39.3","spread":"7.54"},{"groupId":"BG007","value":"42.3","spread":"10.49"},{"groupId":"BG008","value":"39.5","spread":"10.33"},{"groupId":"BG009","value":"41.0","spread":"10.47"},{"groupId":"BG010","value":"38.5","spread":"8.57"},{"groupId":"BG011","value":"39.0","spread":"14.14"},{"groupId":"BG012","value":"39.3","spread":"9.49"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"17"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"83"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"13"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"13"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"80"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"7"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"37"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"23"},{"groupId":"BG008","value":"23"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"18"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"126"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"5"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"23"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"25"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"22"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"129"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"3"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"percentage of participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"100"},{"groupId":"BG003","value":"100"},{"groupId":"BG004","value":"100"},{"groupId":"BG005","value":"100"},{"groupId":"BG006","value":"100"},{"groupId":"BG007","value":"100"},{"groupId":"BG008","value":"100"},{"groupId":"BG009","value":"100"},{"groupId":"BG010","value":"100"},{"groupId":"BG011","value":"100"},{"groupId":"BG012","value":"100"}]}]}]},{"title":"Body Mass Index","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.87","spread":"5.149"},{"groupId":"BG001","value":"27.86","spread":"4.365"},{"groupId":"BG002","value":"28.23","spread":"3.566"},{"groupId":"BG003","value":"28.47","spread":"3.515"},{"groupId":"BG004","value":"24.83","spread":"4.815"},{"groupId":"BG005","value":"26.43","spread":"4.662"},{"groupId":"BG006","value":"29.46","spread":"3.549"},{"groupId":"BG007","value":"27.39","spread":"4.154"},{"groupId":"BG008","value":"27.45","spread":"4.179"},{"groupId":"BG009","value":"28.46","spread":"4.341"},{"groupId":"BG010","value":"28.15","spread":"4.267"},{"groupId":"BG011","value":"32.10","spread":"2.404"},{"groupId":"BG012","value":"27.73","spread":"4.228"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percentage of Participants With Solicited Local Reactions at the Injection Site","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) and pre-listed (that is, solicited) in the e-diary. Solicited local reactions included: pain at the injection site, erythema/redness, and induration/swelling. The intensity of AEs was graded by the study participant. Confirmation by an investigator or medically qualified person was required for all Grade 3 or 4 reactogenicity events. Grades were defined as: Grade 1 - Mild; does not interfere with the study participant's activity; Grade 2 - Moderate; interferes with the study participant's activity; Grade 3 - Severe; prevents study participant's daily activity; and Grade 4 - Potentially life-threatening; emergency room visit or hospitalization for severe pain.\n\nParticipants may have been counted more than once if they reported multiple episodes of the event for the specified doses.","populationDescription":"Analysis was performed on the safety set that included all participants who received at least one dose of the IMP. Participants in the BNT165c 70 mcg + BNT165d 30 mcg Arm/Group did not receive Dose 3; therefore, no data are available post-Dose 3 for this Arm/Group.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)","groups":[{"id":"OG000","title":"BNT165c 10 mcg","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months."},{"id":"OG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nIncludes placebo participants of all dose levels with a 0-2-6 months dose regimen."},{"id":"OG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nDoses were given at 0-1-2 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"classes":[{"title":"Erythema/redness (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Induration/swelling (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Pain at the injection site (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"23"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"0"}]}]},{"title":"Erythema/redness (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Induration/swelling (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Pain at the injection site (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"22"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"}]}]},{"title":"Erythema/redness (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Induration/swelling (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Pain at the injection site (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"0"}]}]},{"title":"Erythema/redness (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Induration/swelling (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Pain at the injection site (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"}]}]},{"title":"Any local reaction grade >=3 - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Any local reaction grade >=3 - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Any local reaction grade >=3 - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Participants With Solicited Systemic Reactions","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) and pre-listed (that is, solicited) in the e-diary. Solicited systemic reactions included: vomiting, diarrhea, headache, fatigue/tiredness, muscle pain/joint pain, and fever. The intensity of AEs was graded by the participant but only an investigator or medically qualified person was able to classify a systemic reaction as Grade 3 or 4. Grades were defined as: Grade 1 - Mild; does not interfere with the study participant's activity; Grade 2 - Moderate; some interference with the study participant's activity; Grade 3 - Severe; prevents the trial participant's daily routine activity; and Grade 4 - Potentially life-threatening; Emergency room visit or hospitalization. Fever was categorized as 38.0 - 38.4 °C, 38.5 - 38.9 °C, 39.0 - 40.0 °C \\& \\>40.0 °C. Participants may have been counted more than once if they reported multiple episodes of the event for the specified doses.","populationDescription":"Analysis was performed on the safety set that included all participants who received at least one dose of the IMP. Participants in the BNT165c 70 mcg + BNT165d 30 mcg Arm/Group did not receive Dose 3; therefore, no data are available post-Dose 3 for this Arm/Group.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)","groups":[{"id":"OG000","title":"BNT165c 10 mcg","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months."},{"id":"OG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nIncludes placebo participants of all dose levels with a 0-2-6 months dose regimen."},{"id":"OG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nDoses were given at 0-1-2 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"classes":[{"title":"Fever (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"}]}]},{"title":"Vomiting (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Diarrhea (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"0"}]}]},{"title":"Headache (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"9"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"0"}]}]},{"title":"Fatigue / tiredness (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"14"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"9"},{"groupId":"OG011","value":"0"}]}]},{"title":"Muscle / joint pain (any grade 1 - 4) - post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"16"},{"groupId":"OG008","value":"14"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"0"}]}]},{"title":"Fever (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"}]}]},{"title":"Vomiting (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Diarrhea (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"0"}]}]},{"title":"Headache (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"0"}]}]},{"title":"Fatigue / tiredness (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"0"}]}]},{"title":"Muscle / joint pain (any grade 1 - 4) - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"0"}]}]},{"title":"Fever (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Vomiting (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Diarrhea (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"}]}]},{"title":"Headache (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"9"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"0"}]}]},{"title":"Fatigue / tiredness (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"0"}]}]},{"title":"Muscle / joint pain (any grade 1 - 4) - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"0"}]}]},{"title":"Fever (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Vomiting (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Diarrhea (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"}]}]},{"title":"Headache (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"1"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"}]}]},{"title":"Fatigue / tiredness (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"}]}]},{"title":"Muscle / joint pain (any grade 1 - 4) - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Any systemic reaction grade >=3 - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Any systemic reaction grade >=3 - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Any systemic reaction grade >=3 - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With at Least One Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered with a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment. The intensity of AEs was graded by the investigator. Grade 1 - Mild; does not interfere with the trial subject's usual function; Grade 2 - Moderate; interferes to some extend with the trial subject's usual function Grade 3 - Severe; interferes significantly with the trial subject's usual function; and Grade 4 - Potentially life-threatening; life-threatening consequences, urgent intervention required. Participants may have been counted more than once if they reported multiple episodes of the event for the different doses.\n\nIncludes all unsolicited AEs and also solicited events that persisted beyond 7 days post-dose, qualify as an SAE, or are delayed local reactions.","populationDescription":"Analysis was performed on the safety set that included all participants who received at least one dose of the IMP. Participants in the BNT165c 70 mcg + BNT165d 30 mcg Arm/Group did not receive Dose 3; therefore, no data are available post-Dose 3 for this Arm/Group.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From administration of each IMP dose (i.e., Dose 1, Dose 2, and Dose 3) up to 28 days after the respective IMP dose","groups":[{"id":"OG000","title":"BNT165c 10 mcg","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months."},{"id":"OG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nIncludes placebo participants of all dose levels with a 0-2-6 months dose regimen."},{"id":"OG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nDoses were given at 0-1-2 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"classes":[{"title":"Post any vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"1"}]}]},{"title":"Post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"0"}]}]},{"title":"Any grade >= 3 AE - post Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"1"}]}]},{"title":"Any grade >= 3 AE - post Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"15"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"19"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]},{"title":"Post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"}]}]},{"title":"Any grade >= 3 AE - post Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With at Least One Medically Attended Adverse Event (MAAE)","description":"An MAAE was defined as an AE for which the participants received medical attention defined as hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.\n\nIncludes all unsolicited AEs and also solicited events that qualify as an MAAE.","populationDescription":"Analysis was performed on the safety set that included all participants who received at least one dose of the IMP.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months.","groups":[{"id":"OG000","title":"BNT165c 10 mcg","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months."},{"id":"OG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nIncludes placebo participants of all dose levels with a 0-2-6 months dose regimen."},{"id":"OG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nDoses were given at 0-1-2 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With at Least One Serious Adverse Event (SAE)","description":"An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death or was life-threatening. It also included any event requiring hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, caused a congenital anomaly or birth defect, or any other event determined as SAE as per medical or scientific judgment.\n\nIncludes all unsolicited AEs and solicited events that qualify as an SAE.","populationDescription":"Analysis was performed on the safety set that included all participants who received at least one dose of the IMP.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months.","groups":[{"id":"OG000","title":"BNT165c 10 mcg","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months."},{"id":"OG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months."},{"id":"OG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nIncludes placebo participants of all dose levels with a 0-2-6 months dose regimen."},{"id":"OG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nDoses were given at 0-1-2 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"30"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"25"},{"groupId":"OG011","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]}]},{"type":"SECONDARY","title":"Descriptive Statistics on Antibody Levels (Including Geometric Means and 95% Confidence Interval) at Assessed Timepoints","description":"For each cohort - Anti-CSP immunoglobulin G","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-03","timeFrame":"Up to 365 days after last received IMP dose","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"AE data was collected from Dose 1 up to 28 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3), i.e., up to 8 months. All SAEs were collected from Visit 0 (Screening) up to end of study, i.e., up to ~20 months.","description":"Analysis was performed on the safety set that included all participants who received at least one dose of the IMP.\n\nPer protocol, solicited local and systemic reactions were not included in the AE analysis unless they continued longer than 7 days post-any IMP administration, were an SAE, or were delayed local reactions. Solicited local and systemic reactions are presented in the respective outcome measures (i.e., outcome measures #1 and #2).","eventGroups":[{"id":"EG000","title":"BNT165c 10 mcg","description":"Cohort 1. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":5,"otherNumAtRisk":10},{"id":"EG001","title":"BNT165c 30 mcg","description":"Cohort 2. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":5,"otherNumAtRisk":10},{"id":"EG002","title":"BNT165c 70 mcg","description":"Cohort 3. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":4,"otherNumAtRisk":10},{"id":"EG003","title":"BNT165c 100 mcg","description":"Cohort 9. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":6,"otherNumAtRisk":10},{"id":"EG004","title":"BNT165d 30 mcg","description":"Cohort 4. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":6,"otherNumAtRisk":10},{"id":"EG005","title":"BNT165c 30 mcg + BNT165d 10 mcg","description":"Cohort 5. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":7,"otherNumAtRisk":10},{"id":"EG006","title":"BNT165c 10 mcg + BNT165d 30 mcg","description":"Cohort 6. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":4,"otherNumAtRisk":10},{"id":"EG007","title":"BNT165c 30 mcg + BNT165d 30 mcg","description":"Cohort 7. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":26,"seriousNumAffected":1,"seriousNumAtRisk":26,"otherNumAffected":9,"otherNumAtRisk":26},{"id":"EG008","title":"BNT165c 70 mcg + BNT165d 30 mcg","description":"Cohort 8. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-2-6 months.","deathsNumAffected":0,"deathsNumAtRisk":30,"seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":10,"otherNumAtRisk":30},{"id":"EG009","title":"BNT165c 30 mcg + BNT165d 10 mcg (0-1-2)","description":"Cohort 10. Participants received 3 intramuscular injections of multi-antigen RNA-based vaccine for active immunization against malaria.\n\nDoses were given at 0-1-2 months.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":7,"otherNumAtRisk":10},{"id":"EG010","title":"Placebo","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nIncludes placebo participants of all dose levels with a 0-2-6 months dose regimen.","deathsNumAffected":0,"deathsNumAtRisk":25,"seriousNumAffected":0,"seriousNumAtRisk":25,"otherNumAffected":8,"otherNumAtRisk":25},{"id":"EG011","title":"Placebo (0-1-2)","description":"Participants received 3 intramuscular injections of isotonic NaCl solution (0.9%).\n\nDoses were given at 0-1-2 months.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":1,"otherNumAtRisk":2}],"seriousEvents":[{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Lymph node pain","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":1,"numAtRisk":2}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":2,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":2,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Axillary pain","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Chest pain","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Chills","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":2,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":2,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Fatigue","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Includes also solicited systemic reactions that continued longer than 7 days post-IMP administration.","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":2,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":2,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Injection site erythema","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Includes also solicited local reactions that continued longer than 7 days post-IMP administration.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Injection site pain","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Includes also solicited local reactions that continued longer than 7 days post-IMP administration.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Malaise","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Peripheral swelling","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Pyrexia","organSystem":"General disorders and administration site conditions","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":2,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":2,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Gastrointestinal viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Otitis media acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Vulvovaginal mycotic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Bone contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Fractured coccyx","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Skeletal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Tooth fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Lipoprotein (a) increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"SARS-CoV-2 test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Vitamin D decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Includes also solicited systemic reactions that continued longer than 7 days post-IMP administration.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":2,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Patellofemoral pain syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":1,"numAtRisk":2}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Includes also solicited systemic reactions that continued longer than 7 days post-IMP administration.","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Illness anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Breast tenderness","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Gynaecomastia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Heavy menstrual bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Hypomenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":1,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":1,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Tonsillar hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":1,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Ingrown hair","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":1,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Pemphigus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":1,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (28.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":1,"numAtRisk":10},{"groupId":"EG006","numAffected":0,"numAtRisk":10},{"groupId":"EG007","numAffected":0,"numAtRisk":26},{"groupId":"EG008","numAffected":0,"numAtRisk":30},{"groupId":"EG009","numAffected":0,"numAtRisk":10},{"groupId":"EG010","numAffected":0,"numAtRisk":25},{"groupId":"EG011","numAffected":0,"numAtRisk":2}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Principal Investigators respectively study sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor."},"pointOfContact":{"title":"BioNTech clinical trials patient information","organization":"BioNTech SE","email":"patients@biontech.de","phone":"+49 6131 9084","phoneExt":"0"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2025-02-04","uploadDate":"2026-05-27T02:45","filename":"Prot_000.pdf","size":1677166},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2025-01-28","uploadDate":"2026-05-27T02:44","filename":"SAP_001.pdf","size":3048296}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2026-07-27","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D008288","term":"Malaria"},{"id":"D016778","term":"Malaria, Falciparum"}],"ancestors":[{"id":"D011528","term":"Protozoan Infections"},{"id":"D010272","term":"Parasitic Diseases"},{"id":"D007239","term":"Infections"},{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"}]}},"hasResults":true}